<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350218</url>
  </required_header>
  <id_info>
    <org_study_id>LSI-2014-0624</org_study_id>
    <nct_id>NCT02350218</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)</brief_title>
  <acronym>PROVISION</acronym>
  <official_title>Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared
      to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST
      levels followed by Eglandin administration were assessed.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak AST level within 7 days of Eglandin administration</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of serum AST level within 5 days of Eglandin administration</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative (percent) change in peak AST level within 7 days of Eglandin administration from baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak ALT levels within 7 days of Eglandin administration</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood flow rate of hepatic artery/vein/portal from baseline at 7th, 14th, 60th, and 120th day from first dose of Eglandin administration</measure>
    <time_frame>7th, 14th, 60th, and 120th day from first dose of Eglandin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total bilirubin/AST/ALT from baseline at 7th, 14th, 30th, and 60th day from first dose of Eglandin administration</measure>
    <time_frame>7th, 14th, 30th, and 60th day from first dose of Eglandin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak total bilirubin levels within 7, 14, 30 and 60 days from first dose of Eglandin administration</measure>
    <time_frame>7, 14, 30 and 60 days from first dose of Eglandin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to total bilirubin recovery (within reference range)</measure>
    <time_frame>day 2~14, day 30, 60,90, 120,150,180 from first dose of Eglandin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant liver survival rate on Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatic artery/vein/portal thrombosis on Day 180</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (other laboratory test, vital sign, adverse event) evaluation</measure>
    <time_frame>All visit(Screening, baseline, day 2~14, day 30, 60,90, 120,150,180)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Eglandin 720㎍</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eglandin® (Alprostadil) 720㎍</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eglandin 360㎍</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eglandin® (Alprostadil) 360㎍</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eglandin</intervention_name>
    <description>Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient</description>
    <arm_group_label>Eglandin 720㎍</arm_group_label>
    <arm_group_label>Eglandin 360㎍</arm_group_label>
    <other_name>Alprostadil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary living donor liver transplantation

          2. Patient received modified right lobe graft

          3. Aged between 19 to 65 years

          4. Informed consent

        Exclusion Criteria:

          1. ABO incompatibility

          2. Dual liver transplant patient from 2 donors

          3. History of liver transplantation or other organ transplantation

          4. Transplantation of other organ(s) at the time of liver transplantation

          5. Use of artificial liver device prior to liver transplantation

          6. UNOS status Ⅰor ⅡA

          7. History of malignant tumor within 5 years

          8. Not included in Milan liver transplant criteria for hepatocellular carcinoma

          9. Patient with WBC &lt; 2,000/mm3 or ANC &lt; 900/mm3 or platelet &lt; 30,000/mm3 at the time of
             screening

         10. Patient exposed to severe systemic infection requiring treatment

         11. Positive response for HIV in either donor or recipient

         12. Prior administration of other investigational product within 30 days (or 5 times the
             half life) from date of screening

         13. Women of childbearing age without effective contraception, breast feeding and pregnant
             women

         14. Substance abuser, patient with metal disorder, and otherwise legally not eligible
             patient

         15. Not eligible to participate at discrete of study investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giwon Song, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea, Republic of</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Giwon Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Living donor</keyword>
  <keyword>Eglandin</keyword>
  <keyword>Alprostadil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

